Emerging MEK inhibitors - PubMed (original) (raw)
Review
doi: 10.1517/14728210903282760.
Linda S Steelman, Steven L Abrams, William H Chappell, Suzanne Russo, Roger Ove, Michele Milella, Agostino Tafuri, Paolo Lunghi, Antonio Bonati, Franca Stivala, Ferdinando Nicoletti, Massimo Libra, Alberto M Martelli, Giuseppe Montalto, Melchiorre Cervello
Affiliations
- PMID: 20151845
- DOI: 10.1517/14728210903282760
Review
Emerging MEK inhibitors
James A McCubrey et al. Expert Opin Emerg Drugs. 2010 Jun.
Abstract
Importance of the field: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. AREAS COVERED BY THIS REVIEW: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series.
What the reader will gain: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells.
Take home message: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.
Similar articles
- Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS. McCubrey JA, et al. Curr Opin Investig Drugs. 2008 Jun;9(6):614-30. Curr Opin Investig Drugs. 2008. PMID: 18516761 - Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ, Der CJ. Roberts PJ, et al. Oncogene. 2007 May 14;26(22):3291-310. doi: 10.1038/sj.onc.1210422. Oncogene. 2007. PMID: 17496923 Review. - Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA, Wilhelm S, Carter C, Kelley SL. Gollob JA, et al. Semin Oncol. 2006 Aug;33(4):392-406. doi: 10.1053/j.seminoncol.2006.04.002. Semin Oncol. 2006. PMID: 16890795 Review. - Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. Ulivi P, et al. J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753. J Cell Physiol. 2009. PMID: 19288493 - Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Yip-Schneider MT, et al. J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3. J Pharmacol Exp Ther. 2009. PMID: 19258520
Cited by
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM. McCubrey JA, et al. Oncotarget. 2012 Oct;3(10):1068-111. doi: 10.18632/oncotarget.659. Oncotarget. 2012. PMID: 23085539 Free PMC article. Review. - U0126 protects cells against oxidative stress independent of its function as a MEK inhibitor.
Ong Q, Guo S, Zhang K, Cui B. Ong Q, et al. ACS Chem Neurosci. 2015 Jan 21;6(1):130-7. doi: 10.1021/cn500288n. Epub 2015 Jan 6. ACS Chem Neurosci. 2015. PMID: 25544156 Free PMC article. - Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
Zhao C, Xiao H, Wu X, Li C, Liang G, Yang S, Lin J. Zhao C, et al. Oncotarget. 2015 Jun 10;6(16):14472-87. doi: 10.18632/oncotarget.3991. Oncotarget. 2015. PMID: 25961376 Free PMC article. - BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer.
Xue P, Zeng F, Duan Q, Xiao J, Liu L, Yuan P, Fan L, Sun H, Malyarenko OS, Lu H, Xiu R, Liu S, Shao C, Zhang J, Yan W, Wang Z, Zheng J, Zhu F. Xue P, et al. EBioMedicine. 2017 Jun;20:50-60. doi: 10.1016/j.ebiom.2017.05.001. Epub 2017 May 4. EBioMedicine. 2017. PMID: 28501528 Free PMC article. - Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.
Liu Z, Xing M. Liu Z, et al. PLoS One. 2012;7(2):e31729. doi: 10.1371/journal.pone.0031729. Epub 2012 Feb 16. PLoS One. 2012. PMID: 22359623 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous